Sartorius Stedim Biotech2019年年度报告.pdf

《Sartorius Stedim Biotech2019年年度报告.pdf》由会员分享，可在线阅读，更多相关《Sartorius Stedim Biotech2019年年度报告.pdf（186页珍藏版）》请在三个皮匠报告上搜索。

1、Sartorius Group2019 Annual Report91)Underlying=excluding extraordinary items2)After non-controlling interest,adjusted for extraordinary items and non-cash amortization,as well as based on the normalized financial result,including the corresponding tax effects for each of these items3)2015 adjusted f

2、or stock split;rounded values4)Amounts suggested by the Supervisory Board and the Executive Board of Sartorius AG5)Since 2019 and as a result of the change in IFRS 16 accounting principles,CAPEX has been based on cash flow instead of balance sheet computation;CAPEX restated for 2018:233.2 million;CA

3、PEX ratio restated for 2018:14.9%All figures are given in millions of according 2019 2018 2017 2016 2015 to the IFRS,unless otherwise specifiedOrder intake,sales revenue and earningsOrder intake 1,939.5 1,662.5 1,501.4 1,334.7 1,172.7Sales revenue 1,827.0 1,566.0 1,404.6 1,300.3 1,114.8Underlying EB

4、ITDA1)495.8 405.0 353.2 325.4 263.2Underlying EBITDA1)as a%of sales revenue 27.1 25.9 25.1 25.0 23.6Relevant net profit2)209.3 175.6 144.0 132.6 107.4Research and development costs 95.6 78.2 68.8 59.4 52.5 Financial data per share3)Earnings per share2)per ordinary share(in)3.06 2.56 2.10 1.93 1.59 p

5、er preference share(in)3.07 2.57 2.11 1.94 1.60Dividende per ordinary share(in)0.704)0.61 0.50 0.45 0.37 per preference share(in)0.714)0.62 0.51 0.46 0.38 Balance sheetBalance sheet total 2,844.3 2,526.9 2,297.7 1,753.0 1,437.2Equity 1,081.2 973.4 806.6 736.8 644.8Equity ratio(in%)38.0 38.5 35.1 42.

6、0 44.9 FinancialsCapital expenditures5)225.6 237.8 209.4 152.1 113.1Capital expenditures as a%of sales5)12.3 15.2 14.9 11.7 10.1Depreciation and amortization 132.6 113.4 98.3 75.7 58.9Cash from operating activities 377.2 244.5 206.5 170.4 124.4Net debt 1,011.3 959.5 895.5 485.9 344.0Gearing(underlyi